Teva gets labeling supplement approved for injectable Paclitaxel
FDA cleared a labeling change for Teva's Paclitaxel injection under ANDA075184 on September 11, 2026.
Teva Pharmaceuticals had one regulatory update on file this week.
- The FDA approved a labeling supplement, submission number 22, for Teva's injectable Paclitaxel (6MG/ML) under ANDA075184, with a standard review priority and a submission status date of 2026-09-11.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.